Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.
about
Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.A perspective on multi-target drug discovery and design for complex diseases.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
P2860
Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Panobinostat (Farydak): A Nove ...... d Refractory Multiple Myeloma.
@en
type
label
Panobinostat (Farydak): A Nove ...... d Refractory Multiple Myeloma.
@en
prefLabel
Panobinostat (Farydak): A Nove ...... d Refractory Multiple Myeloma.
@en
P2860
P1476
Panobinostat (Farydak): A Nove ...... d Refractory Multiple Myeloma.
@en
P2093
Donald Moore
P2860
P304
P577
2016-05-01T00:00:00Z